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Abstract
Background: Selection of amino acid substitutions associated with resistance to nucleos(t)ide-analog (NA) therapy in the
hepatitis B virus (HBV) reverse transcriptase (RT) and their combination in a single viral genome complicates treatment of
chronic HBV infection and may affect the overlapping surface coding region. In this study, the variability of an overlapping
polymerase-surface region, critical for NA resistance, is investigated before treatment and under antiviral therapy, with
assessment of NA-resistant amino acid changes simultaneously occurring in the same genome (linkage analysis) and their
influence on the surface coding region.
Methodology/Principal Findings: Serum samples obtained from chronic HBV-infected patients at pre-treatment and during
sequential NA treatment with lamivudine, adefovir, and entecavir were analyzed by ultra-deep pyrosequencing (UDPS)
using the GS-FLX platform (454 Life Sciences-Roche). The pre-treatment HBV quasispecies was not enriched with NA-
resistant substitutions. The frequencies of this type of substitutions at pre-treatment did not predict the frequencies
observed during lamivudine treatment. On linkage analysis of the RT region studied, NA-resistant HBV variants (except for
rtA181T) were present in combinations of amino acid substitutions that increased in complexity after viral breakthrough to
entecavir, at which time the combined variant rtL180M-S202G-M204V-V207I predominated. In the overlapping surface
region, NA-resistant substitutions caused selection of stop codons in a significant percentage of sequences both at pre-
treatment and during sequential treatment; the rtA181T substitution, related to sW172stop, predominated during
treatment with lamivudine and adefovir. A highly conserved RT residue (rtL155), even more conserved than the essential
residues in the RT catalytic motif YMDD, was identified in all samples.
Conclusions: UDPS methodology enabled quantification of HBV quasispecies variants, even those harboring complex
combinations of amino acid changes. The high percentage of potentially defective genomes, especially in the surface
region, suggests effective trans-complementation of these variants.
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Introduction
The hepatitis B virus (HBV) is a DNA virus that replicates via
reverse transcription of an RNA intermediate [1] with rapid viral
turnover (.1011 virions per day) [2] and high mutation rates
(.1025 nucleotide substitutions/site/year) [3], despite the ex-
tremely high overlap of its coding regions [4]. Therefore, the virus
circulates as a complex quasispecies, undergoing continuous
changes due to competition and interactions between the genetic
variants produced [5]. Chronic HBV infection (CHB) affects 350
million people worldwide and is a leading cause of liver cirrhosis
and hepatocellular carcinoma [6]. Currently, five oral nucleos(t)ide
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analogues (NAs) are approved for CHB treatment in many parts of
the world: lamivudine (LMV), adefovir-dipivoxil (ADV), entecavir
(ETV), telbivudine (LdT) and tenofovir (TDF) [6,7]. These drugs
prevent viral replication by inhibiting the HBV reverse transcrip-
tase (RT), but do not avoid formation of the covalently closed
circular DNA (cccDNA), the main intracellular intermediate of
HBV which is responsible for viral persistence, and they clear it at
very slow rates [7–9]. Therefore long-term treatment is needed to
maintain suppression of replication [8,9]. These therapies may
result in selection of antiviral-resistant HBV variants from the
HBV quasispecies pool over time, leading to treatment failure and
disease progression. In treatment-naı¨ve patients, selection of NA-
resistant variants is highly probable with LMV, intermediate with
ADV and LdT, and minimal or even zero with ETV and TDF,
which are currently recommended as first-choice therapies against
CHB [6,7].
Currently, identification of HBV genotypic NA resistance is
mainly performed by PCR amplification and Sanger sequencing
or the INNO-LiPA line probe reverse hybridization assay (LiPA),
which detect NA resistance amino acid (aa) substitutions present in
the HBV quasispecies in proportions of 20% and between 5%–
10%, respectively [7]. With these methods the frequencies of each
mutation cannot be measured, and it is impossible to determine
whether several mutations are combined in the same sequence
(mutation linkage). This is an important limitation because the
addition of compensatory or secondary NA resistance aa
substitutions to primary resistance substitutions in NA-resistant
genomes (which usually reduce their replication efficiency in
relation to wild-type variants), may enhance the replication of
these genomes or even give rise to multidrug resistant (MDR)
variants [10,11]. As an alternative to LiPA and direct sequencing,
molecular cloning enables analysis of single DNA molecules,
thereby surpassing the detection limits of the other techniques.
Nevertheless, this methodology is complex and time-consuming
because analysis of at least 100 clones is required to detect variants
present in 1% of the quasispecies. These limitations can now be
overcome by ultra-deep pyrosequencing (UDPS) technology based
on the GS-FLX platform (454 Life Sciences-Roche), which enables
quantitative analysis of thousands of clonally amplified sequences
[12] up to 400 nucleotides (nts) in length. With this technique,
minor variants in the HBV quasispecies can be detected and
quantified, including those with combinations of changes in the
same sequence. In HIV infection, UDPS has been used to detect
clinically relevant minority drug-resistance mutants with much
higher sensitivity (,1%) than cloning [13,14]. It has been
suggested that quantification of minor drug-resistance mutants in
treatment-experienced HIV-infected patients may be helpful when
planning subsequent antiretroviral regimens [15]. A similar
approach has been used to analyze HBV quasispecies in the RT
and the overlapping hepatitis B surface antigen (HBsAg) coding
regions in drug-naive (untreated) and drug-resistant patients
[16,17]. However, the simultaneous presence of various NA
resistance-related aa substitutions in the same genome was not
analyzed.
In the present study, a coding region where HBV polymerase
(P) and surface (S) open reading frames (ORFs) overlap was
clonally analyzed by UDPS with standard GS-FLX technology
(the only method available when the study was designed), which
allows sequencing of DNA fragments up to 250 bp in length,
including the fusion primers (see Patients and Methods). The
region analyzed extends from codon rt148 to rt208 in the P ORF,
which includes most RT codons corresponding to reported
relevant NA-resistant aa substitutions (rtI169T, rtV173L,
rtL180M, rtA181T/V, rtT184S/A/I/L/G/C/M, rtA194T,
rtA202C/G/I, rtM204V/I [7], rtW153Q [18], rtV191I [19]
and rtV207I [20]), and spans a part of the S ORF, from codon
s140 to s200, containing the C-terminal region of the immuno-
dominant epitope ‘‘a determinant’’ (codon s124 to s147) (Figure 1).
This was done to exploit the capability of UDPS technology to
quantify variants in extremely low percentages in the viral
quasispecies in order to study the variability of the overlapping
coding region before NA treatment and during sequential
treatment. Our rationale for performing this research was that
in the absence of antiviral treatment, ultra-deep analysis of the
variability in this region might identify conserved positions in the
RT region with a potentially essential functional role in the HBV
polymerase and would be helpful to establish whether the
percentage of HBV NA-resistant variants in the baseline
quasispecies could predict their subsequent selection by a
particular NA treatment. Furthermore, during sequential NA
treatment, the ability of UDPS to analyze clonally amplified
sequences would enable study of the simultaneous presence of
various aa substitutions (linkage analysis) related to treatment
failure in the same genome and detection of enrichment in MDR
variants. This is of particular relevance in LMV resistance, which
increases the probability of developing cross-resistance to subse-
quent treatments with ETV or ADV [21–24]. In addition,
enrichment of the HBV quasispecies in MDR variants could
result in changes in epitopic regions of HBsAg that could
potentially affect virion assembly, stability or infectivity, owing to
the complete overlap between the P and S ORFs [4,25]. Thus, aa
substitutions present in the S ORF were also studied to determine
the influence of MDR variant enrichment.
Results
A total of 350 744 reads from 8 serum samples were obtained
after filtering the UDPS results with the GS-Amplicon-Variant-
Analysis software included in GS-FLX platform. To increase the
sensitivity and accuracy of UDPS, these reads were additionally
filtered by an automated computational algorithm that excluded
those likely to contain artifactual single-base changes based on
Poisson distribution [13]. By this approach, 245 565 reads (13 670
to 62 450 per sample) were validated. In each sample, the most
highly represented nucleotide sequence was designated ‘‘master’’.
Alignment between these master sequences is shown in Dataset S1,
and translations into amino acids in the P and S ORFs are shown
in Dataset S2 and Dataset S3, respectively.
UDPS analysis of pre-treatment patient samples
A total of 141 581 validated reads were obtained from the 4
pre-treatment patient samples (1, 2, 3 and 4A). In each sample, the
master sequence matched the consensus sequence obtained by
Sanger method. Each validated read was aligned with the master
sequence from the corresponding sample to calculate the
frequency of each aa change relative to the master. Using this
method, we found that the frequency of aa substitutions associated
with NA treatment resistance was not significantly different from
that of the remaining aa changes; the differences approached
significance only in patient 4 (P= 0.09) (Table 1). On calculation of
the average percentage of each aa change in the 4 baseline
populations, 13 changes were found at average frequencies of
$0.1% (Table S1), and 4 of them are known to confer NA
resistance: rtA181T (0.10%), rtV191I (0.23%), rtA194T (0.11%),
and rtM204I (0.15%). The dominant sequence in patient 2 was
accompanied by around 5% of sequences carrying substitutions
rtH148Y, rtR153W, rtI187L and rtL199V (Figure 2). In addition,
substitutions rtD205N and rtD206N, both of which affect essential
HBV Amino Acid Changes Linkage and Conserved Sites
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residues from the YMDD catalytic motif, showed frequencies of
0.26% and 0.13%, respectively.
Patient 1 had detectable percentages of rtA181T and rtM204V/
I by UDPS in the baseline quasispecies, but neither was selected
during LMV treatment (Table 2). Furthermore, the patient did not
experience viral breakthrough (VBK), defined as an increase in
serum HBV-DNA of at least 1 log10IU/mL compared to the
lowest value during treatment, confirmed by real-time PCR [6]. In
patients 2 and 3, LMV resistance was associated with predominant
selection of rtL180M and rtM204V, despite the fact that higher
percentages of rtA181T and/or rtM204I were detected by UDPS
at baseline (Table 2). In patient 4, rtA181T and rtM204I were the
most prevalent aa substitutions at pre-treatment according to
UDPS results; however only rtA181T was detected by LiPA
(INNO-LiPA HBV DR v2 assay) and direct sequencing at LMV
VBK (Table 2). Furthermore, rtL180M and rtM204V, which were
present in frequencies below the mismatch error (0.03%) at pre-
treatment, accounted for around 5% of the quasispecies at LMV
VBK (sample 4C in Table 3). On linkage analysis, combinations of
polymerase variants were not detected in any of the baseline
populations, even though more than 60 000 sequences were
examined in the sample from patient 3.
In the overlapping S region (codons s140–s200), 21 substitutions
were present at an average frequency of $0.1% (data not shown).
In the ‘‘a determinant’’, only substitution sG145R (0.11%), the
main HBsAg immune escape variant [26], was present at .0.1%.
Among these 21 substitutions, 9 were located in the epitope
flanked by codons s156 and s175 (TH-s156/s175), which has been
reported to stimulate CD4+ T-lymphocytes in subjects receiving
the anti-HBV vaccine [27]. Of note, a substantial part of these
substitutions (4 out of 9) resulted in stop codons (*) (sW156*,
sW163*, sW165* and sW172*), giving rise to proteins with
Figure 1. Fragment of HBV genome analyzed by UDPS. A. Initially a 224-bp fragment of the HBV genome was amplified with the fusion
primers, obtaining a 262-bp amplicon. After trimming both primer ends, a 180-nucleotide fragment was analyzed. The fragment contains the B and C
domains of the HBV RT in the polymerase ORF, spanning rtY148 to rtV208, and a region of the overlapping surface ORF, from sT140 to sY200,
including a part of the main hydrophilic region, which contains a small portion of the C-terminus of the immunodominant epitope ‘‘a determinant’’,
framed in green in the sequence below. B. The sequence framed in black corresponds to that of the 180-nucleotide fragment analyzed and shows its
translation into aa in the P (above, depicted in blue) and S (below, depicted in red) ORFs. Most of the main codons related to nucleos(t)ide resistance
(framed in blue), and the overlapping codons in the S ORF that may give rise to immune escape or stop codons (framed in red) are located within the
analyzed fragment. Codons rt233, rt236, and rt250 were not considered relevant for the aims of this study and were not analyzed.
doi:10.1371/journal.pone.0037874.g001
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significant aa deletions. In fact, 8 of the 21 substitutions led to a
stop codon, which, taken together, represented 0.98% to 2.1% of
the 4 baseline viral populations. Four of these 8 stop codons
affected RT positions associated with NA resistance (sW172*
related to rtA181T, sW182* to rtV191I, sW196* to rtM204I, and
sW199* to rtV207I), at frequencies of 0.20% to 0.30%,
significantly higher than the artifactual error (0.03%).
Figure 2. Overall frequency of amino acid substitutions at each reverse transcriptase position. Each bar represents the sum of
frequencies of all amino acid changes occurring in each reverse transcriptase position. Each bar with a different color in the same position
corresponds to one of the 8 samples studied in the 4 patients. Among these positions rtL155 (framed in red) was the least variable. Samples 1, 2, 3, 4A
and 4B were obtained prior to antiviral treatment, whereas samples 4C, 4D and 4E correspond to completion of lamivudine, adefovir, and entecavir
treatments, respectively.
doi:10.1371/journal.pone.0037874.g002
Table 1. Enrichment in amino acid changes related to nucleos(t)ide analog resistance in the pre-treatment quasispecies.
Patient (sample) Resistance-related aa changes (Mean frequency) Other aa changes (Mean frequency) P-value
1 (N=32 737) 0.04 0.06 0.42
2 (N=13 670) 0.09 0.07 0.99
3 (N=62 450) 0.06 0.05 0.53
4 (4A) (N=32 724) 0.08 0.03 0.09
aa, amino acid; N, number of reads obtained by ultra-deep pyrosequencing.
The mean frequency of amino acid changes related to nucleos(t)ide analog resistance (rtI169T, rtV173L, rtL180M, rtA181T/V, rtT184S/A/I/L/G/C/M, rtA194T, rtA202C/G/I,
rtM204V/I [7], rtW153Q [18], rtV191I [19] and rtV207I [20]) obtained by ultra-deep pyrosequencing at pre-treatment was compared with the mean frequency of the
remaining amino acid changes.
doi:10.1371/journal.pone.0037874.t001
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UDPS analysis of conserved amino acid residues
Assessment of the frequencies of synonymous (ds) nt changes
(which do not imply an aa change) and non-synonymous (dn) nt
changes (which imply an aa change) in the P ORF of the 4 pre-
treatment samples (Table S2) revealed 16 conserved positions with
a dn #0.1%, among which only residue rtL155 showed a dn
,0.03% (virtually unchanging) at pre-treatment and during
treatment (Figure 2). In the essential YMDD catalytic motif, only
residue rtY203 was included within the 16 positions, whereas
rtD205 and rtD206 showed relatively high variability, an
unexpected finding considering their essential role in polymerase
catalytic activity [28]. In the S ORF, ten positions showed a dn
#0.1% (Table S2). Three of them were located in the ‘‘a
determinant’’: sP142 and sN146, associated with viral infectivity
[29], and sC147, a cysteine critical for secretion of HBV particles
[30]. Other potentially essential positions included in the fragment
analyzed, such as sS174, proposed as a ‘‘hot spot’’ for Surface/
Core protein-to-protein interactions based on a predicted
3Dmodel of the surface protein [30], were not among the most
highly conserved.
To evaluate the relative variability of the P and S ORFs along
the region analyzed, we subtracted the percentage of variability of
the S region from the percentage of variability of RT region. This
calculation was performed taking into account that any change in
the first nt of the P codons affects the third nt of the overlapping S
codon (P1/S3), while the second and third nts of P affect the first
and second nts of the overlapping S codon (P2–3/S1–2). In both
calculations (P1/S3 and P2–3/S1–2), S was more variable than P.
Moreover, P1/S3 showed that in the C-terminal end of the UDPS-
analyzed fragment (rtR192-rtV208 corresponding to sV184-
sY200), which includes the YMDD catalytic domain, the P ORF
was significantly better conserved than the S ORF, whereas in the
N-terminal end (rtY148-rtY158 corresponding to sT140-sI150),
which includes several residues important for viral infectivity such
as those of the ‘‘a determinant’’ [29,31], the S protein was more
highly conserved (Figure 3).
Longitudinal UDPS analysis of serum samples from a
patient with multidrug resistance during sequential
therapy
A total of 136 708 validated reads corresponding to 5 serial
samples from patient 4, (4A and 4B at pre-treatment and 4C to 4E
in sequential treatment) were analyzed. The most variable RT aa
substitutions in the 5 samples, sorted by decreasing SD value, are
shown in Table 3. The 10 most variable substitutions (highest SD
value), rtL180M, rtM204V, rtS202G, rtV207I, rtA181T,
rtV173L, rtI169T, rtV191I, rtM204I and rtT184A, are known
to be associated with NA resistance. Interestingly, immediately
after these well known NA-resistant variants, in positions 11 and
12, we found the rare variants rtA181S and rtA200V, which are
associated with ADV and L-nucleoside analogue (LMV and LdT)
resistance, respectively [32]. In contrast, rtR153Q and rtA194T,
also associated with NA resistance, were less variable (positions 25
and 26 in Table 3).
Changes occurring in the HBV quasispecies of the RT region
studied over a 42-month period in the absence of treatment were
assessed by comparative UDPS analysis of samples 4A and 4B.
The consensus sequence was identical in both samples and the
variants showed low comparative changes in frequency, except for
rtV191I, which increased from 0.6% (4A) to 1.1% (4B) (Table 3).
At the time of LMV VBK (sample 4C), percentages of rtA181T
(71.7%), rtM204V (5.6%), and rtL180M (5%) notably increased
relative to baseline samples, as did other LMV resistance
substitutions, particularly rtV191I (5.8%), rtV207I (3.9%), and
Table 2. Relationship between frequencies of lamivudine resistance-related amino acid changes detected at pre-treatment and
their selection at lamivudine viral breakthrough in the four patients.
Patient (sample) RT aa changes Pre-treatment relative frequency by UDPS (%) Selection at LMV VBK
1 (N=32 737) rtL180M 0 No
rtA181T 0.07 No
rtM204I 0.07 No
rtM204V 0.06 No
2 (N=13 670) rtL180M 0 LiPA & Seq
rtA181T 0.18 No
rtM204I 0.35 No
rtM204V 0.09 LiPA & Seq
3 (N=62 450) rtL180M 0 LiPA & Seq
rtA181T 0.07 No
rtM204I 0.09 No
rtM204V 0.05 LiPA & Seq
4 (4A) (N=32 724) rtL180M 0 LiPA
rtA181T 0.09 LiPA & Seq
rtM204I 0.08 No
rtM204V 0 LiPA
aa, amino acid; LiPA, INNO-LiPA HBV DR v2 assay; LMV, lamivudine, N, number of reads obtained by UDPS; RT, reverse transcriptase; Seq, direct sequencing; UDPS, ultra-
deep pyrosequencing; VBK, virologic breakthrough (increase in serum HBV-DNA levels, confirmed by real-time PCR, of at least 1 log10IU/mL compared with the lowest
value during NA treatment [6]).
Comparison between the relative frequencies of lamivudine-resistant variants detected by UDPS at pre-treatment and their subsequent detection by reverse
hybridization (INNO-LiPA HBV DR v2 assay) and/or direct sequencing at lamivudine viral breakthrough in the four patients.
doi:10.1371/journal.pone.0037874.t002
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rtV173L (1.4%), although to a lesser extent. The ETV-associated
substitution rtS202G also increased slightly (0.15%) (Table 3). At
the end of ADV (sample 4D), rtA181T, which was detected by
LiPA, remained as the major variant (64%) (Table 3 and Figure 4),
whereas rtV191I (8%) continued increasing. Moreover, the
number of minor substitutions with frequencies $0.1% increased
with respect to LMV VBK (Table 3). At ETV VBK (sample 4E),
two variants previously detected by LiPA at LMV VBK were
strongly selected, rtL180M (99.3%) and rtM204V (99.4%) (Table 3
and Figure 4). In addition, other NA-resistant variants related with
resistance to ETV and detected by Sanger sequencing also
increased significantly at ETV VBK: rtV173L (18.2%), which was
detectable by LiPA, rtS202G (80.9%) and rtI169T (17.3%),
inconsistently observed by Sanger [22] (Table 3 and Figure 4). We
also observed an increase in other NA-resistant variants that have
not been previously related to ETV resistance, such as rtV207I
(80.9%), detected by Sanger sequencing, and the rare substitution,
rtA200V (0.38%) (Table 3 and Figure 4).
In the overlapping S ORF, 51 aa substitutions were present at
frequencies $0.1% in at least one of the 4A to 4E samples (data
not shown). The most variable positions were those that
overlapped RT residues associated with NA resistance, particu-
larly sI195M, related to rtM204V, present in 5.6% and 99% of
sequences at LMV VBK and ETV VBK, respectively. As observed
in the baseline quasispecies, a significant portion of the 20 most
frequent variants (highest average substitution frequencies in the 5
samples) led to stop codons (sW156*, sW172*, sW182*, sW191*,
sW196* and sW199*), especially at LMV VBK and at the end of
ADV, mainly due to mutation sW172*, related to rtA181T,
(71.7% and 64%, respectively) and sW182*, related to rtV191I,
(5.8% and 8%, respectively). The total frequency of genomes
carrying a stop codon was 80%, 74%, and 4.4% at LMV, ADV,
and ETV VBK, respectively. These 20 variants did not include the
immune escape variant sG145R, detected in relatively high
frequencies at pre-treatment, but otherwise included the variants
sS167L, sW172C, and sW172*, located at the minimal recognized
sequence (positions s165 to s172) of the TH-s156/s175 epitope
[27]; among these, sS167L showed a continuous percentage
increase from pre-treatment to ETV-VBK (sample 4A: 0.2%, 4B:
0.7%, 4C: 1.1%, 4D: 1.3%, 4E: 4%).
For each sample, nt and aa divergences were assessed as the
percentage of sequences different from the master sequence in the
first baseline sample (sample 4A), and as the percentage of
sequences different from each sample’s master sequence. In each
quasispecies, nt divergence was always higher than aa divergence
in both analyses. Nucleotide divergence in relation to the baseline
master sequence was similar in both pretreatment samples (9.72%
and 8.23%), but significantly increased during antiviral treatments
(82.5% after LMV, 70.84% after ADV and 99.69% after ETV).
Amino acid divergence was higher in the S ORF than in P in both
pre-treatment samples using both calculations, but under antiviral
treatments, aa divergence in the S ORF continued higher than in
the P ORF when related to the master sequence of each sample,
while they tended to equalize in relation to the baseline master
sequence (Table 4).
UDPS linkage analysis to establish the combination of
the most variable residues in the same sequence
The 10 most variable RT substitutions observed during
sequential NA treatment, blindly selected after SD sorting and
all associated with NA resistance (rtL180M, rtM204V, rtS202G,
rtV207I, rtA181T, rtL173V, rtI169T, rtV191I, rtM204I, and
rtT184A) (Table 3), were included in the linkage analysis. Among
all their possible combinations, the sequence with no mutations in
these positions (baseline combination: BC) showed the highest
variability during NA treatment. This BC sequence was largely
dominant at pre-treatment (98.5%), but greatly decreased at VBK
during sequential NA treatment, especially at ETV VBK (0.3%)
(Table 5 and Figure 5).
Linkage analysis yielded two main findings: First, the 10 most
variable aa substitutions were mainly present in variant combina-
tions, the only exception being rtA181T, which was the single
substitution in 64.1% of sequences at LMV VBK and 56.5% at the
end of ADV (Table 5). This substitution was also found in
combination with rtV191I in a significant percentage of variants
(4.4% at LMV VBK and 6.6% at ADV end) (Table 5). Second, at
ETV VBK, rtI169T and/or rtS202G, which are typically
Table 3. Frequencies of amino acid substitutions with the
highest variability during sequential treatment in each of the
five treatment samples.
Amino acid
substitutions 4A 4B 4C 4D 4E SD
L180M 0 0.01n 5.02 0.6 99.3 48.8
M204V 0.02n 0 5.6 0.7 99.4 48.7
S202G 0 0.02n 0.15 0.08 80.9 40.4
V207I 0.01n 0.02n 3.9 0.8 80.9 39.7
A181T 0.09 0.05 71.7 64 0.23 39.2
V173L 0.05 0.04 1.4 0.13 18.2 8.9
I169T 0 0 0.04 0 17.3 8.7
V191I 0.59 1.09 5.8 8.0 0.02n 3.8
M204I 0.08 0.03 1 0.09 0 0.5
T184A 0.01n 0 0.04 0.06 0.91 0.44
A181S 0.02n 0.01n 0.47 0.23 0 0.22
A200V 0.02n 0.01n 0.01n 0.04 0.38 0.18
I162T 0.08 0.06 0.18 0.16 0 0.08
K149N 0.02n 0 0.06 0.17 0 0.08
L157M 0.19 0.14 0.19 0.16 0.02n 0.08
K154Q 0.05 0.01n 0.05 0.18 0.06 0.08
R153W 0.06 0.01n 0.05 0.18 0.03 0.07
V163I 0.10 0.04 0.17 0.14 0.03 0.07
V173M 0.07 0.04 0.15 0.10 0 0.06
K154T 0.01n 0.03 0.10 0.13 0 0.06
I169L 0.03 0.03 0.15 0.12 0.08 0.06
R167H 0.06 0.03 0.02n 0.04 0.12 0.05
V207M 0.13 0.05 0.04 0.07 0.12 0.04
G152R 0.08 0.04 0.04 0.03 0.11 0.03
R153Q 0.13 0.06 0.06 0.12 0.07 0.03
A194T 0.07 0.07 0.05 0.10 0.06 0.02
NUMBER OF
SEQUENCES
32724 35662 25289 19740 23249
SD, standard deviation;
n, Frequencies below the mismatch error rate (0.03%).
Frequencies of reverse transcriptase amino acid substitutions with the highest
variability during sequential antiviral treatment, according to their standard
deviation, in the 5 samples analyzed in patient 4 (4A and 4B correspond to pre-
treatment, and 4C, 4D and 4E correspond to completion of lamivudine,
adefovir, and entecavir, respectively). Substitutions are arranged in descending
order, from the most to the least variable. Frequencies of substitutions $0.1%
in any sample are shown in bold. Substitutions selected for linkage analysis are
shown in bold.
doi:10.1371/journal.pone.0037874.t003
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associated with ETV resistance, always appeared linked to the
LMV resistance signature (rtL180M-rtM204V), in keeping with
previous reports [22] (Table 5), whereas rtV207I, which has not
been previously associated with ETV resistance, unexpectedly
appeared in most of the highly frequent combinations and always
together with other variants, especially rtM204V (Table 5). In
order to confirm whether the association of rtV207I and rtM204V
was specific to this patient or a more general phenomenon, results
from a first-generation LiPA strip (which included NA resistance-
related substitutions in codons rt204 and rt207 [33]) of 50 patients
who had failed LMV treatment were retrospectively checked.
Thirty-nine percent of them showed rtV207I and rtM204V/I
(data not shown). Three patients carrying rtM204V and rtV207I
had been subsequently treated with ETV, and two of them had
rapid VBK after an initial ETV response.
The predominant presence and complexity of the combined aa
substitutions was particularly evident at ETV VBK, in which the
main variant combination was rt180M-202G-204V-207I (72.4%),
followed by rt169T-173L-180M-204V (10%) and rt169T-173L-
180M-202G-204V-207I (4.6%) (Table 5 and Figure 5). To support
the reliability of the frequencies of combinations detected, the 4E
sample was analyzed by molecular cloning. In an analysis of 23
clones, the rt180M-202G-204V-207I combination was also the
most prevalent (65% of clones), followed by rt169T-173L-180M-
204V (22%), and rt180M-204V (13%). UDPS showed that many
of the most prevalent combinations detected at ETV VBK were
present in $0.1% at LMV VBK, such as: rt180M-202G-204V-
207I (0.1%), rt180M-204V (0.3%), rt180M-204V-207I (1.4%),
and rt173L-180M-204V (0.6%) (Table 5 and Figure 5). Among
them, combined variants carrying only LMV resistant mutations,
such as rtV173L-rtL180M-rtM204V and rtL180M-rtM204V,
increased in frequency from LMV to ETV VBK (from 0.6% to
1.3% and from 0.3% to 3.2%, respectively) (Table 5 and Figure 5).
Discussion
Massive UDPS analysis enabled sensitive baseline detection of
minor viral populations associated with NA resistance, as has been
reported [34], and identification of highly variable and conserved
residues. In addition, UDPS proved to be a powerful technique for
quantitative study of the dynamics of HBV populations resulting
from the multiple evolutionary pressures of sequential NA therapy.
The capability to clonally analyze thousands of sequences
disclosed combinations of aa substitutions occurring in the same
genome during antiviral treatment.
Identification of mutations in extremely low percentages with an
acceptable degree of confidence is limited by the number of
independent template molecules obtained from the sample
analyzed, the coverage or number of reads obtained per base,
and the number of artifactual errors generated during PCR
amplification and pyrosequencing [13]. For these reasons, all the
samples selected for the current study carried a high HBV viral
load (.105 IU/mL), and the high-fidelity DNA polymerase Pfu
turbo linked to a Poisson-based computational algorithm [13] was
used to bypass the artifactual errors. With this approach, variants
comprising as little as 0.03% of the HBV quasispecies could be
detected. UDPS analysis showed that aa changes known to be
associated with NA resistance above this detection limit (rtA181T,
rtV191I, rtA194T and rtM204I) were present in low percentages
(ranging from 0.07 to 0.59) in the baseline HBV quasispecies,
Figure 3. Differences in variability throughout the fragment of reverse transcriptase and overlapping surface region analyzed. In
the pre-treatment samples (1 to 4A), each bar represents the difference between the average frequency of amino acid substitutions in each reverse
transcriptase (RT) position and its overlapped amino acid in the surface (S) region, assuming that any substitution in the first nucleotide of an RT
codon affects the third nucleotide of the overlapping S codon. Bars with positive values indicate positions with a higher tolerance for amino acid
substitutions in RT than in S, whereas the opposite is indicated by bars with negative values.
doi:10.1371/journal.pone.0037874.g003
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probably representing a background due to the natural dynamics
of the viral quasispecies. Moreover, variant combinations were not
detected in the baseline quasispecies. These results suggest that if
the resistance changes were present (which seems likely because of
their strong selection in the longitudinally analyzed patient 4), they
would be in percentages below the detection limit. Therefore,
higher sensitivity than is reported here seems to be required for
detecting combined variants at baseline. In the sequentially treated
patient, the relative frequency of NA-resistant substitutions in the
baseline quasispecies did not seem to be predictive of subsequent
LMV treatment outcome or RT variants selected at VBK.
The high sensitivity of UDPS also made possible identification
of conserved residues. The residue rtL155 was found to be the
most highly conserved at both pre-treatment and throughout
sequential treatment, a previously unreported finding. According
to a structural analysis based on a 3Dmodel of HBV RT [35], this
leucine residue is located at the external surface of RT (Figure S1),
and has high hydrophobicity, features that suggest a role in
protein-to-protein interactions. The low overall frequency of aa
substitutions in rtL155 was even lower than that observed in
residues deemed essential for viral polymerase function, such as
rtY203, rtD205 and rtD206 from the conserved YMDD catalytic
motif [28,36]. Considering the essentiality of rtD205 and rtD206,
which are part of the catalytically essential aspartic acid triad of
HBV RT [28], a higher than expected variability was found
(.0.1% in one case). In this sense, it has been reported that
substitutions in rtD205 result in replication-defective HBV
variants that can be trans-complemented in vitro by wild-type
Figure 4. Longitudinal virologic and biochemical outcome of patient 4. Thick arrows indicate the sampling time and thin arrows specify
mutations detected by reverse hybridization (INNO-LiPA HBV DR v2 assay) and/or direct sequencing, which are shown in bold in samples analyzed by
UDPS. * This variant was not consistently observed by Sanger sequencing.
doi:10.1371/journal.pone.0037874.g004
Table 4. Nucleotide and amino acid divergences in the S and
P ORFs in each sample from patient 4.
4A 4B 4C 4D 4E
NT Master 9.72 8.23 82.50 70.84 99.69
Baseline
Master
P Master 7.60 5.57 82.03 69.70 99.69
S Master 9.64 7.34 80.59 70.37 99.67
NT Master 9.72 8.23 41.63 51.33 35.53
Sample
Master
P Master 7.60 5.57 39.65 48.17 31.01
S Master 9.64 7.34 41.05 50.56 33.95
NT Master, nucleotide master sequence; P Master, amino acid master sequence
in polymerase (P) ORF; S Master, amino acid master sequence in surface (S) ORF.
Nucleotide and amino acid divergences in samples from patient 4 (4A and 4B
correspond to pre-treatment, and 4C, 4D and 4E correspond to completion of
lamivudine, adefovir, and entecavir, respectively). In each sample, divergences
were calculated as the percentage of all sequences different from the master of
the first baseline sample processed (sample 4A) (Baseline Master), and the
percentage of all sequences different from the master of the sample where they
were obtained (Sample Master).
doi:10.1371/journal.pone.0037874.t004
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polymerases [37–39]. This mechanism may explain the finding of
genomes with aa substitutions in rtD205, which may replicate
through trans-complementation with a helper wild-type HBV
polymerase in the same hepatocyte.
The HBV genome has an extremely overlapping structure [4].
With UDPS, we were also able to study epitopic regions of the S
ORF that overlap the RT region. In the baseline viral populations,
the S ORF showed significant percentages of substitutions that
lead to a stop codon (1%–2%). These mainly overlapped RT
positions related to NA resistance variants, and some of them
delete important envelope residues involved in viral infectivity
and/or possible interactions with core proteins [29,30]. The
envelope stop codon variant sW172*, which is related to the major
NA-resistant variant rtA181T, became the most highly represent-
ed following LMV and ADV treatments, yielding a major viral
population that is defective in secretion of viral particles, as
reported by Warner et al. [23]. This strongly suggests that
secretion of genomes harboring the sW172* substitution would be
enabled by trans-complementation with a functional S protein
from other HBV genomes occurring in the same quasispecies, as
previously suggested [24]. Trans-complementation of envelope-
defective variants may be favored by the huge excess of HBsAg
production during chronic infection (1000- to 10 000-fold excess
in relation to complete viral particles) [40]. Thus, envelope-
competent genomes might produce enough HBsAg for their own
envelops and those of the defective genomes, even as minor viral
populations. These findings suggest that the large excess of HBsAg
may have evolved to offset the presence of envelope stop codons.
Regarding the relative variability of the P and S ORFs, we
found that the N-terminal region (rtY148-rtY158 corresponding to
sT140-sI150) included in the ‘‘a determinant’’, which is the main
target for anti-HBs neutralizing antibody [41,42], was more
conserved in the S than in the P ORF. This may be explained by
the close relationship of this epitope with infectivity [31].
Moreover, the only variant found in proportions above 0.1%
was the well-known immune escape substitution sG145R [26],
which modifies the antigenicity of the ‘‘a determinant’’, while viral
particles remain infective [29]. Interestingly, despite the relevance
and high degree of conservation of the ‘‘a determinant’’, RT
residue rtL155 was more highly conserved than its overlapped
amino acids in the S ORF, sN146 and sC147, both essential for
the structure and function of this determinant [29,30]. Contrary to
what was observed for the N-terminal region, in the C-terminal
(rtR192-rtV208 corresponding to sV184-sY200), where the
essential YMDD motif of RT is located, the P ORF was more
conserved than the S ORF. These observations support the notion
that although the polymerase and surface proteins share the same
nt sequence, they evolve independently to preserve their essential
functions, as reported by van Hemert et al. [30].
Figure 5. Changes in percentages of reverse transcriptase variants during follow-up of patient 4. Frequencies of the most variable
variants in the 5 samples from patient 4 (ie, those detected in frequencies $1% by linkage analysis in any of the samples) are shown in a pie chart for
each sample. Each variant has been numbered as sorted in Table 5 (by decreasing SD of the frequency), except for the variant with no mutations in
any of the positions included in the analysis. This variant, which was the most variable of all, is designated baseline combination.
doi:10.1371/journal.pone.0037874.g005
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In the longitudinal study of the patient sequentially treated with
LMV, ADV, and ETV monotherapies, the blind SD-based
algorithm ranked the 7 NA resistance-related aa substitutions
previously detected by routine analysis (rtL180M, rtM204V,
rtS202G, rtV207I, rtA181T, rtV173L and rtI169T) as the most
variable, and 5 additional NA resistance substitutions (rtV191I,
rtM204I, rtT184A, rtA181S and rtA200V) immediately after
them. These findings confirm the utility of this methodology as a
‘‘scanning tool’’ to detect, without any previous assumptions, the
most relevant substitutions associated with MDR, even some that
would not be found unless specifically checked. The use of UDPS
as a scanning tool linked to its ability to quantify the frequencies of
HBV variants could provide a measure of their relative sensitivity
to different NA therapies. In this sense, the rtA181T variant,
Table 5. Linkage analysis of the most variable amino acid substitutions during sequential treatment.
Combined variants 4A 4B 4C 4D 4E SD
169I-173V-180L-181A-184T-191V-202S-204M-207V (BC) 98.54 98.51 19.60 33.80 0.30 43.5
180M-202G-204V-207I 0.00 0.00 0.10 0.01n 72.36 36.2
181T 0.09 0.05 64.08 56.45 0.10 34.9
169T-173L-180M-204V 0.00 0.00 0.00 0.00 10.00 5.0
181T-191I 0.00 0.00 4.39 6.57 0.01n 3.3
169T-173L-180M-202G-204V-207I 0.00 0.00 0.01n 0.00 4.59 2.3
180M-204V 0.00 0.00 0.28 0.01n 3.20 1.6
180M 0.00 0.00 1.94 0.27 0.11 0.9
180M-202G-204V 0.00 0.00 0.00 0.00 1.82 0.9
180M-204V-207I 0.00 0.00 1.38 0.22 1.19 0.7
181T-204V-207I 0.00 0.00 1.24 0.18 0.00 0.6
173L-180M-204V 0.00 0.00 0.59 0.05 1.26 0.6
191I 0.59 1.08 0.78 1.32 0.00 0.6
173L-180M-184A-204V 0.00 0.00 0.00 0.00 0.89 0.4
169T-180M-202G-204V-207I 0.00 0.00 0.00 0.00 0.76 0.4
169T-173L-180M-204V-207I 0.00 0.00 0.00 0.00 0.74 0.4
181T-204V 0.00 0.00 0.75 0.07 0.00 0.4
173L-180M-202G-204V-207I 0.00 0.00 0.00 0.00 0.55 0.3
204V-207I 0.00 0.00 0.57 0.11 0.00 0.3
173L-180M 0.00 0.00 0.55 0.06 0.00 0.3
169T-180M-184A-202G-204V-207I 0.00 0.00 0.00 0.00 0.53 0.3
204V 0.02n 0.00 0.47 0.06 0.00 0.2
204I 0.08 0.03 0.43 0.02n 0.00 0.2
169T-173L-180M-184A-204V 0.00 0.00 0.00 0.00 0.40 0.2
173L-180M-184A-202G-204V-207I 0.00 0.00 0.00 0.00 0.36 0.2
181T-207I 0.00 0.00 0.26 0.21 0.00 0.1
169T-180M-204V 0.00 0.00 0.00 0.00 0.26 0.1
181T-204I 0.00 0.00 0.26 0.07 0.00 0.1
169T-173L-180M-202G-204V 0.00 0.00 0.00 0.00 0.18 0.1
180M-184A-204V 0.00 0.00 0.00 0.00 0.18 0.1
169T-173L-180M-184A-202G-204V-207I 0.00 0.00 0.00 0.00 0.17 0.1
204I-207I 0.00 0.00 0.15 0.00 0.00 0.1
207I 0.01n 0.02n 0.13 0.08 0.00 0.1
173L-181T 0.00 0.00 0.12 0.02n 0.00 0.1
173L 0.05 0.03 0.06 0.01n 0.00 0.0
184A 0.05 0.01n 0.05 0.02n 0.00 0.0
202G 0.00 0.02n 0.01n 0.04 0.00 0.0
NUMBER OF SEQUENCES 32724 35662 25289 19740 23249
SD, standard deviation;
n,Frequencies below the mismatch error rate (0.03%); BC, Baseline combination (the master combination of positions where substitutions with the highest variation,
shown in bold in Table 3, were located).
Frequencies of combinations (linkage) of the 10 amino acid substitutions with the highest standard deviation of frequencies in the 5 sequential treatment samples from
patient 4 (4A and 4B correspond to pre-treatment and 4C, 4D and 4E correspond to completion of lamivudine, adefovir, and entecavir, respectively). The variant
combinations are presented in decreasing order (from most to least variable). Frequencies of combinations $1% are shown in bold.
doi:10.1371/journal.pone.0037874.t005
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which strongly increased from pre-treatment to LMV and slightly
decreased during ADV therapy, appeared to be more resistant to
LMV than to ADV, in agreement with its previous phenotypic
characterization [24]. With this approach, the sensitivity to
different NAs of the less common resistant variants (rtV191I,
rtA181S, and rtA200V) found among the most variable ones can
also be studied. In this particular case, percentages of rtV191I
increased during LMV and ADV, mainly in combination with the
major variant rtA181T, suggesting a compensatory role of rtV191I
to restore its replicative fitness. During ETV, percentages of both
rtA181T and rtV191I dramatically decreased, indicating sensitiv-
ity to this drug. The variation in percentages of rtA181S followed a
pattern similar to that of rtA181T, but with a less intense effect
(moderately increased after LMV VBK, maintained during ADV,
and undetectable after ETV treatment), therefore, position rt181
had a major role in resistance to multiple NAs in the longitudinally
followed patient. Moreover, rtA181S is linked to the sW172C
substitution in the minimal recognized sequence of the surface
epitope TH-s156/s175 [27]; hence, it is likely to provide immune
escape. In the case of the rtA200V substitution, although
previously associated with resistance to LMV and LdT [32], in
this longitudinal study it was only found significantly increased at
ETV VBK, suggesting some ‘‘decreased sensitivity’’ to ETV. In
the overlapping S ORF, quantitative UDPS analysis was applied
to study the sensitivity of the HBV variants to immune pressure. In
this sense, the increase in percentages of NA-resistant rtV191I in
the absence of treatment concurs with its reported link to humoral
immune response escape by an association with the surface stop
codon sW182* [19], recently related to liver disease progression
[43]. In addition, the sS167L variant, associated with a silent RT
substitution in rtL175 (CTC to CTT), showed a continuous
percentage increase in the absence of treatment and during follow-
up. sS167 is located in the minimal recognized sequence of the
TH-s156/s175 epitope, and changes in this residue have been
reported in patients simultaneously showing HBsAg and anti-HBs
antibodies [42]. Therefore, it would seem to be subjected to
immune selection rather than treatment selection. Hence, the
findings in the RT and S ORFs observed in the sequentially
treated patient suggest that UDPS may have value as a
‘‘phenotype-like’’ assay to assess the influence of any type of
selective pressure on the composition of viral quasispecies.
Quantitative UDPS analysis is not only useful to analyze
particular positions of the HBV genome, but also to examine
changes in the variability of the quasispecies by quantifying the
global nt and aa divergences of its sequences in relation to the
master sequence. In the longitudinally studied case, the high
increase in nt divergence over several antiviral treatments reflects
adaptation of the viral quasispecies by selection of antiviral-
resistant variants. The higher divergence in nt sequences in
comparison to aa sequences is likely related to genetic code
degeneration. Furthermore, the higher aa divergence in S than in
P ORFs observed when related to the master sequence of each
sample may be evidence of immune pressure over envelope
proteins, which are more prone to globally evolve than polymerase
due to functional constrictions, especially in the absence of
antiviral treatment. However, P and S divergences tended to
equalize when they were analyzed in relation to the baseline
master sequence (sample 4A). This pattern may reflect an evolutive
pressure over P ORF positions affecting in parallel the
corresponding overlapped S ORF positions.
The superiority of GS-FLX technology for clonally sequencing
relatively long single DNA molecules as compared to other
massive sequencing platforms [44] enabled study of particular
combinations of two or more aa substitutions in the same genome
by linkage analysis. To facilitate computation and interpretation of
these analyses, we focused on the 10 most variable substitutions,
assuming that they would be the most relevant to study HBV
adaptation to the pressure of sequential NA treatment. Using this
approach, we found that in our MDR patient, with the single
exception of rtA181T, all these substitutions were mainly found in
combinations in all the samples studied. The substitution patterns
were particularly complex at ETV VBK, with rtL180M-S202G-
M204V-V207I being the main combination. This pattern was
confirmed by molecular cloning, and had already been detected as
a minor population at LMV VBK, followed by rt169T-173L-
180M-204V and rt169T-173L-180M-202G-204V-207I (6 muta-
tions in a single genome). In this particular case, the frequency of
the LMV resistance signature (rtL180M-M204V) alone showed a
considerable increase at ETV VBK relative to its frequency after
LMV, as also occurred with the more complex variant rtV173L-
L180M-M204V. This suggests that LMV-resistant mutants have
slightly reduced sensitivity to ETV, as reported by phenotypic
assays [22,45,46]. Unexpectedly, the rtV207I variant, which to
date has only been associated with low sensitivity to LMV and
resistance to famciclovir [20], was present in the most prevalent
combined variants at ETV VBK (81% of sequences) and was also
significantly increased at LMV VBK. This variant was mainly
selected in combination with rtM204V, a fact that strongly
suggests a compensatory role to restore the replicative efficiency of
complex HBV variants carrying rtM204V, likely to compromise
the success of ETV. Although these observations were obtained in
a single case, this hypothesis is supported by our retrospective
review of LiPA results. However, in contrast to this hypothesis, the
sensitivity of the LMV-resistant signature to ETV did not change
when the signature was combined with rtV207I in a previous
phenotypic study [46]. Therefore, additional phenotypic analysis
should be performed taking into account the complexity of the
variants detected here by linkage analysis.
Our study has some limitations. Only a small number of serum
samples could be analyzed because of the high cost of the
technique and complexity of the computational analysis. More-
over, because only a single MDR patient was longitudinally
analyzed, the results obtained regarding changes in the viral
quasispecies under the effect of antiviral treatments require
corroboration by further studies examining additional patients.
In addition, due to the 250-bp-length limitation of the standard
GS-FLX chemistry, the relevant NA-resistant substitutions,
rtI233V and rtN236T linked to ADV treatment failure, and
rtM250I/V linked to ETV failure [7], located outside the B and C
HBV RT functional domains, were excluded from the fragment
analyzed. However, this last limitation was not considered relevant
because we only selected patients who did not show NA resistant
substitutions outside the region analyzed, as assessed by LiPA and/
or direct sequencing during follow-up.
To summarize, UDPS detected minor variants comprising less
than 0.1% of the HBV viral quasispecies. Nonetheless, the
information provided did not enable prediction of which resistant
aa substitutions would be selected during treatment. Additional
studies are needed to determine at what frequency HBV variants
become clinically relevant. However, the high sensitivity of this
technology has resulted in some unexpected findings: first, the high
degree of conservation of residue rtL155 and a significant
percentage of defective genomes at baseline (with variations in
essential residues of the RT active site or stop codons in the S
ORF) that became the predominant population after LMV and
ADV treatments. These results suggest that the HBV quasispecies
has an active trans-complementation mechanism enabled by
coinfection of cells with multiple variants. Second, as tested in one
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sequentially treated patient, assessing and ranking the variability of
aa substitutions through sequential treatment using a ‘‘blinded’’
algorithmic method driven by an objective variability measure
(SD) of their frequencies highlighted the most important substi-
tutions occurring during this period, with no need for previous
knowledge about HBV variants and their resistance to antiviral
treatments. Therefore, this method can potentially act as a
‘‘scanning tool’’ to detect new resistant variants in viral
quasispecies, and indicates a role as a ‘‘phenotype-like’’ method
that provides information on the relative susceptibility of these
variants to any type of selective pressure (eg, antiviral therapies or
immune pressure). Quantitative UDPS analysis was also useful to
analyze the global variability of the HBV quasispecies and its
evolution, by quantifying the nt and aa divergences of its
sequences. Lastly, the partial picture of reality provided by UDPS
analysis of individual substitutions is significantly improved by
linkage analysis, which allows detection and quantification of
variant combinations, which seem to be the most common cause
of resistance in anti-HBV therapy in our sequentially treated
patient. In conclusion, UDPS offers significant advantages for the
study of viral quasispecies, although currently its potential is
mainly limited by its high cost. As new applications for this
technology are developed, it is likely that the cost will significantly
decrease.
Methods
Ethics statement
The study protocol was approved by the Ethics Committee for
Clinical Investigation of University Hospital Vall d’Hebron.
Informed written consent from participating patients was ob-
tained, according to the Declaration of Helsinki.
Patients and samples
Serum samples from 4 CHB patients were included in the study.
To obtain comparable results, patients were selected according the
following criteria: first, all were hepatitis B e antigen (HBeAg)-
positive and all had HBV genotype A, subgenotype A2, assessed
by direct sequencing and alignment as previously reported [35];
second, they were initially treated with LMV and no resistance
variants were found at baseline, as assessed by LiPA (INNO-LiPA
HBV DR v2 assay, Innogenetics, Ghent, Belgium) or direct
sequencing; and third, HBV NA-resistant variants outside the B
and C domains of the RT were not selected in any case after NA
treatment. The baseline characteristics and outcome of initial
LMV treatment are summarized in Table 6. Patient 1 was only
treated with LMV and showed virologic response (undetectable
HBV-DNA levels by real-time PCR within 48 weeks of therapy
[6]) and HBeAg seroconversion (loss of HBeAg with detection of
anti-HBe antibodies) (Table 6). In contrast, patients 2, 3 and 4
experienced VBK with selection of resistant variants (Table 6). In
patients 2 and 3, ADV was added after LMV VBK, and both
showed virologic response with undetectable HBV-DNA levels
after stopping LMV. In addition, patient 3 lost HBeAg after 3
years of ADV+LMV and additionally lost HBsAg in the following
3 years with ADV monotherapy. In patient 4, LMV failure was
associated with emergence of the rtA181T variant (Figure 4). The
patient, who was subsequently treated with ADV and ETV
monotherapies, showed no response to ADV and had VBK after
ETV with selection of resistant variants (Figure 4). TDF was then
added to ETV, and the patient achieved virologic response
without HBeAg loss up to the time this study was performed
(Figure 4).
Eight serum samples were selected for UDPS analysis: 1 sample
obtained before starting LMV therapy in patients 1, 2 and 3; and 5
consecutive samples from the sequentially treated patient 4, among
which 2 samples (4A and 4B) were obtained before starting LMV
in a 42-month period without treatment, and 1 sample each was
obtained at the end of LMV (4C), ADV (4D) and ETV (4E)
treatment (Figure 4).
HBV genome region analyzed by UDPS
To perform linkage analysis of the major NA-resistance-related
aa substitutions in the RT region, a single fragment clustering
these substitutions was analyzed. At selection of this fragment, the
idea was to include the HBV RT B and C domains, which
comprised all NA-resistant mutations previously detected by LiPA
or direct sequencing at VBK in each patient (Table 6 and Figure 4)
(third patient’s inclusion criteria). In addition, to assess the changes
in the most important epitopes of the overlapped S ORF, the
fragment included the largest part possible of the C-terminal
region of the immunodominant epitope ‘‘a determinant’’, which
had the main immunotherapy escape mutation sG145R, associ-
ated with the rtW153Q NA compensatory variant [18]. Finally,
we had to restrict the length of the fragment to 250 bp as required
by the standard GS-FLX technology, the only one available when
the study was designed. These criteria were fulfilled by a fragment
of 224 bp, in which 180 bp were analyzed after excluding the
known sequences of the primers. The fragment selected covers an
HBV P-S overlapping sequence spanning codons rt148 to rt208 in
the P ORF and codons s140 to s200 in the S ORF (Figure 1). NA-
resistance-related aa substitutions outside the B and C domains,
such as rtI233V, rtN236T and rtM250I/V, were not considered
relevant for the aims of the study, since they had not been detected
during follow-up in any of the patients studied.
PCR amplification of the region analyzed
A 746-bp fragment (nt 246 to 992) of HBV-DNA including the
region for UDPS analysis was amplified by PCR using primers F2
and R2 [47]. A second PCR run amplified the specific UDPS
fragment (nt 551 to 775) with fusion primers HBVRTfw: 59-
GCCTCCCTCGCGCCATCAGATGTTTCCCTCATGTTGCTG-
39 and HBVRTrv 59-GCCTTGCCAGCCCGCTCAGCTGTACA-
GACTTGGCCCCCA-39 (the 59 adaptor sequences that act as
binding sites for the emulsion PCR and pyrosequencing reaction
of the UDPS system, both ending with the TCAG barcode, are
shown in italics). This second PCR run generated a 262-bp
amplicon (Figure 1). To minimize misincorporation errors, the
high-fidelity Pfu Turbo DNA polymerase (Stratagene, Agilent
Technologies, La Jolla, USA) was used in both PCR runs [13,48].
The length and quality of the amplicons obtained were verified by
automated chip-based microcapillary electrophoresis (Agilent
2100 Bioanalyzer instrument, Agilent Technologies, Santa Clara,
USA) and quantified (Quant-it PicoGreen dsDNA fluorescent
Assay Kit, Invitrogen, Carlsbad, USA). Ten mL of each amplicon,
with a concentration $0.5 ng/mL ($107 copies/mL) underwent
UDPS with the GS-FLX platform, according to the manufactur-
er’s protocol.
The 746-bp amplicon obtained in the first PCR round from
sample 4E was directly cloned, as previously described [49].
Quantification of artifactual errors
The main error source for the detection of single-base changes
when deep-sequencing an amplicon seems to be polymerase
mismatch errors [50]. To quantify these errors as has been done in
previous studies [13,16], a DNA clone with a known sequence was
UDPS-analyzed in triplicate and sequenced by the conventional
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Sanger method. Any differences between UDPS reads and the
Sanger sequence were considered UDPS errors. In addition,
UDPS has been reported to be more error prone in homopoly-
meric regions (3 or more identical consecutive nts flanked by non-
identical bases) [12]. For this reason, different arrays of mismatch
frequencies (m values) were generated in homopolymeric and non-
homopolymeric regions (Table 7).
Computational analysis
Data accuracy of the UDPS reads was initially validated as
recently reported [34]. However, to exclude reads with low-
confidence single-base changes, we approximated the distribution
of mismatch errors using Poisson distribution [13] instead of an
internal control sequence [34] (details in Table 7). Variants with a
low probability of being erroneous (P,0.05) were included in the
analysis.
Table 6. Baseline characteristics of the patients included and outcome during LMV treatment.
BASELINE CHARACTERISTICS LAMIVUDINE TREATMENT
Patient Age Gender HBV-DNA (log10IU/mL) ALT (IU/L) Duration (months) Type of Response Resistant variants at VBK
1 70 F 6.54 112 28 HBeAg seroconversion and virologic response None
2 52 M 6.08 53 51 Partial virologic response (2.2 logD) and VBK (7.7 log*) rtM204V+rtL180M
3 54 M 7.08 73 39 Partial virologic response (4.2 logD) and VBK (7.3 log*) rtM204V+rtL180M
4 32 M 8.44 39 19 Partial virologic response (2.6 logD) and VBK (7.2 log*) rtM204V+rtL180M+rtA181T
F, female; M, male; HBeAg, hepatitis B e antigen; log, HBV-DNA (log10IU/mL);
D, HBV-DNA decrease 6 months after beginning lamivudine treatment relative to baseline;
*, HBV-DNA levels at virologic breakthrough, which determined the end of lamivudine treatment and occurred at the end of the period indicated in the Duration
column.
HBV-DNA was quantified using real-time PCR (Cobas Ampliprep-Taqman, Roche; sensitivity 20 IU/mL), and resistant variants were determined in the sample obtained at
viral breakthrough by LiPA (INNO-LiPA HBV DR v2 assay) and/or direct sequencing. The response to lamivudine treatment was defined as:
- HBeAg seroconversion: Loss of hepatitis B e antigen with detection of anti-HBe antibodies.
- Virologic response: undetectable HBV-DNA levels by real-time PCR within 48 weeks (12 months) of therapy [6].
- Partial virologic response: decrease in HBV DNA of more than 1 log10IU/mL, but detectable HBV DNA by real-time PCR, assessed at 24 weeks (6 months) of treatment,
for lamivudine [6].
- VBK: virologic breakthrough - increase in serum HBV-DNA levels of at least 1 log10IU/mL compared to the lowest value during NA treatment, confirmed by real-time
PCR [6].
doi:10.1371/journal.pone.0037874.t006
Table 7. Poisson model for quantification of artifactual errors.
Homopolymeric (r = 1) A C T G
A 1 2.3461026 2.0461026 3.4961026
C 4.9861026 1 3.5661025 1.9561025
T 3.9961026 2.9161026 1 2.0461026
G 1.5061024 3.9261025 4.4061026 1
Non-homopolymeric (r = 2) A C T G
A 1 2.9361026 1.4761026 7.5361026
C 4.8361026 1 1.0161025 3.2061026
T 1.2161026 7.3961026 1 1.7761025
G 4.2361025 1.4161026 2.9161026 1
The nucleotide (nt) expected to be found at a given position is expressed as ntsi , ‘‘s’’ indicates sequence position (s = 1 to 180) and ‘‘i’’ indicates nt of the master
sequence found in ‘‘s’’ position (1 = A, 2 = C, 3 = T, 4 = G). An observed variant ‘‘s’’ is represented as ntsj , where ‘‘j’’ indicates the nt substitution (1 = A, 2 = C, 3 = T, 4 = G); k
s
j
represents the number of occurrences of an ‘‘i’’ to ‘‘j’’ substitution (ntsi to nt
s
j ) in the N reads covering an ‘‘s’’. The distribution of mismatch errors was approximated using
Poisson distribution, extended to make the parameters depend on the type of mismatch error (12 possible substitutions [A:C, A:T, A:G, C:A, C:T, C:G, T:A, T:C, T:G, G:A,
G:C, G:T]) and the region type (homopolymeric/non-homopolymeric). Thus, assuming ksj as a Poisson-distributed random variable, the P-value associated with this test
was calculated as:
p~1{
Xk
s
j
{1
l~0
e{l:l
l!
l
In which l is the expected number of errors ntsi to nt
s
j at ‘‘s’’ site: l~mijr|N with r referring to the type of region (r = 1 for homopolymeric and r = 2 for non-
homopolymeric), with mijr values from the array of mismatch frequencies shown in the table. For example, if a T to A change is found (i = 3 and j = 1) at a certain site in a
non-homopolymeric region, (r = 2), then m312~1:21|10
{6 and l~m312|N~1:21|10
{6|N . In a type of filter strategy, after applying the Poisson formula, variants
with a low probability of being erroneous (P,0.05) were included in the analysis.
doi:10.1371/journal.pone.0037874.t007
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Longitudinal variability of the HBV quasispecies in the
sequentially analyzed MDR patient was assessed by a ‘‘blind’’
algorithm-driven method, which consists of ranking each aa
substitution according to the standard deviation (SD) of its
frequencies in the validated reads from each of the 5 samples
from patient 4, assuming that the substitution with the highest SD
value through the 5 consecutive samples would be the most
variable.
Validation of UDPS data
The Poisson-based statistical filter was validated using an
independent HBV RT clone, processed as the patient samples.
The empirical distribution of mismatch errors in the clone yielded
an average of 0.007%, but in 4 positions, errors were higher than
0.02% and lower than 0.03%. Therefore, the sensitivity of UDPS
to detect mutations was limited by a mismatch error rate of 0.03%,
a value similar to the rate reported using a restriction target
sequence as internal control [34]. Nonetheless, to focus the
analysis on the most significant changes, the quantifications and
biological conclusions reported here are based on mutations
comprising $0.1% of the viral population.
Statistical analysis
The frequencies of aa substitutions known to be associated with
resistance to NA treatment were compared to the remaining aa
changes in the baseline viral populations using the Mann-Whitney
U test with significance set at a P-value of ,0.05. The analysis was
performed with SPSS, version 15.0 (SPSS Inc., Chicago, USA).
Acceptance of a nucleotide substitution was decided by Poisson
distribution modeling (details in Table 7).
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